Yoram Sharon, DO
Internal Medicine · Green Brook, NJNPI 1649202193
Payments from drug & device makers
Across 579 payments — averaging $14.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Novo Nordisk$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$765
- Merck$610
- Lilly USA, LLC$404
- Daiichi Sankyo Inc.$389
- plus $2K from 22 others
What the payments were for
- Food & beverage$8,319100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 106 | $2,874 |
| Novo Nordisk | 93 | $1,067 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 65 | $765 |
| Merck | 58 | $610 |
| Lilly USA, LLC | 41 | $404 |
| Daiichi Sankyo Inc. | 43 | $389 |
| Exact Sciences | 15 | $337 |
| AbbVie(2 entities) | 34 | $334 |
| Axsome Therapeutics, Inc. | 22 | $327 |
| Genentech USA, Inc. | 29 | $265 |
| Amarin Pharma, Inc. | 14 | $178 |
| Boehringer Ingelheim | 13 | $175 |
| Jazz Pharmaceuticals Inc. | 16 | $160 |
| Abbott | 4 | $66 |
| Arbor Pharmaceuticals, Inc. | 4 | $55 |
| GSK | 4 | $54 |
| Kowa Pharmaceuticals America, Inc. | 3 | $41 |
| Mission Pharmacal Company | 2 | $35 |
| Amgen(2 entities) | 2 | $30 |
| Bausch Health US, LLC | 2 | $26 |
| Pfizer | 2 | $25 |
| Boston Scientific | 1 | $18 |
| Gilead | 1 | $15 |
| Grifols USA, LLC | 1 | $15 |
| Nabriva Therapeutics, PLC | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Astellas Pharma US Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$1,442
- BREZTRI$1,129
- AIRSUPRA$661
- SYMBICORT$104
- BEVESPI AEROSPHERE$104
How this compares
$8,319 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 59 | $59,061 |
| JanuviaSitagliptin Phosphate | 33 | $45,854 |
| OzempicSemaglutide | 20 | $29,278 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $23,107 |
| MounjaroTirzepatide | 14 | $18,440 |
| EliquisApixaban | 11 | $18,054 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $17,352 |
| LinzessLinaclotide | 14 | $13,570 |
| PremarinEstrogens, Conjugated | 15 | $3,856 |
| Atorvastatin Calcium | 291 | $2,135 |
| Levothyroxine Sodium | 171 | $1,746 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 62 | $1,588 |
| Losartan Potassium | 186 | $1,369 |
| Rosuvastatin Calcium | 72 | $1,330 |
| Celecoxib | 20 | $1,223 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet | $610 | $63,20645 claims |
| AstraZenecaFarxiga | $2,874 | $59,06159 claims |
| Novo NordiskOzempic | $1,067 | $29,27820 claims |
| GSKTrelegy Ellipta | $54 | $23,10724 claims |
| PfizerEliquis, Premarin | $25 | $21,90926 claims |
| Lilly USA, LLCMounjaro | $404 | $18,44014 claims |
| AbbVieLinzess, Synthroid | $334 | $14,28328 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Green Brook
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.